Health and Healthcare
Is InflaRx Sunk by a Midstage Skin Condition Study?
Published:
Last Updated:
InflaRx N.V. (NASDAQ: IFRX) shares were destroyed on Wednesday after the firm announced results from its midstage trial in patients suffering from moderate to severe hidradenitis suppurativa (HS).
Prior to these results, this company was just shy of a $1 billion market cap — $968 million to be specific. Now, following the results, the market cap sits at roughly $102 million.
HS is a painful and debilitating chronic inflammatory skin disease with limited treatment options.
The primary endpoint of the trial was a dose-response signal, assessed by the Hidradenitis Suppurativa Clinical Response (HiSCR) score at week 16. Unfortunately, the primary statistical analysis by multiple-comparison procedure modeling showed no significant dose response for the IFX-1 treatment.
IFX-1 was well tolerated. Overall, 72% of placebo-treated patients experienced a treatment-emergent adverse event when compared to 66% of the combined IFX-1 treated groups. The most common treatment-emergent adverse events were exacerbation of hidradenitis suppurativa and nasopharyngitis.
Othmar Zenker, chief medical officer of InflaRx, commented:
We are disappointed that we were not able to demonstrate a significant signal on dose response for the treatment with IFX-1. While we are still analyzing additional data, we note that the trial demonstrated an unusually high placebo HiSCR rate at week 16.
Shares of InflaRx traded down about 90% to $3.94 Wednesday morning. The 52-week range is $3.30 to $53.10, and the consensus price target is $56.75.
24/7 Wall St.The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
